---
_schema: default
id: 18840
date: 2024-11-22
title: >-
    What genetic alterations have been observed in Mary's cancer?
article_title: >-
    What genetic alterations have been observed in Mary's cancer?
date_format: MMM DD, YYYY
post_on_text: Posted on
seo:
  title: QuickTakes | Health Studies
  page_description: >-
    This content discusses the genetic alterations observed in Mary's Stage IV squamous cell lung cancer, including PIK3CA mutations, EGFR mutations, and FGFR1 amplification, highlighting the significance of molecular profiling for personalized treatment strategies.
  page_keywords: >-
    Mary, Stage IV, lung cancer, squamous cell carcinoma, PIK3CA mutations, EGFR mutations, FGFR1 amplification, genetic alterations, tumor behavior, treatment responses, PI3K-AKT signaling, personalized treatment, molecular profiling
author: QuickTakes
question: >-
    What genetic alterations have been observed in Mary's cancer?
answer: >-
    In the case of Mary, who has been diagnosed with Stage IV squamous cell lung cancer (SQCLC), several genetic alterations have been observed that are relevant to her cancer type. The landscape of genetic alterations in squamous cell lung cancer includes various mutations and aberrations that can influence tumor behavior and treatment responses.\n\n1. **PIK3CA Mutations**: PIK3CA mutations have been reported in approximately 6.5% of lung squamous cell carcinomas. These mutations lead to increased lipid kinase activity and constitutive activation of the PI3K-AKT signaling pathway, which is crucial for cell growth and survival. Specific mutations, such as E545K and E542K, disrupt the interaction between the regulatory and catalytic subunits of the PI3K, while the H1047R mutation affects the activation loop of the kinase, resulting in continuous signaling.\n\n2. **EGFR Mutations**: Although epidermal growth factor receptor (EGFR) mutations are more common in lung adenocarcinomas, they are relatively rare in squamous cell lung carcinoma, with a reported prevalence of only 3% to 18%. This limits the effectiveness of EGFR-targeted therapies in this cancer type.\n\n3. **FGFR1 Amplification**: Alterations in the fibroblast growth factor receptor (FGFR) pathway, including FGFR1 amplification, have been identified in some cases of squamous cell lung cancer. This alteration may serve as a potential therapeutic target, as drugs like the FGFR inhibitor AZD4547 are being investigated in clinical trials.\n\n4. **Other Genetic Alterations**: The genetic landscape of squamous cell lung cancer is complex, and ongoing research is focused on identifying additional driver mutations and copy-number alterations that could be targeted therapeutically. The identification of these alterations is crucial for developing personalized treatment strategies.\n\nOverall, the genetic alterations observed in Mary's cancer highlight the importance of molecular profiling in understanding the disease and guiding treatment decisions. As research continues, the identification of specific "driver" mutations will be essential for improving therapeutic outcomes in patients with squamous cell lung cancer.
subject: Health Studies
file_name: what-genetic-alterations-have-been-observed-in-marys-cancer.md
url: /learn/health-studies/questions/what-genetic-alterations-have-been-observed-in-marys-cancer
score: -1.0
related_article1:
    id: 18826
    title: >-
        How was the diagnosis of Stage IV Squamous Cell Lung Cancer confirmed in Mary's case?
    subject: Medicine
    url: /learn/medicine/questions/how-was-the-diagnosis-of-stage-iv-squamous-cell-lung-cancer-confirmed-in-marys-case
related_article2:
    id: 18837
    title: >-
        How is the pRB protein altered in Mary's cancer cells?
    subject: Medicine
    url: /learn/medicine/questions/how-is-the-prb-protein-altered-in-marys-cancer-cells
---

&nbsp;